A comprehensive digital approach to helping patients manage type 2 diabetes, combining continuous glucose monitoring (CGM) devices, wearables and a mobile app, has been sh
The Novo Nordisk Foundation is not a charitable organisation owned by the pharma company Novo Nordisk. In fact, it’s the other way around, more or less.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.